Prognostic factors for patients with cancer-associated dermatomyositis: a retrospective, multicentre cohort study of 73 patients
Authors' conclusion
This study provides strong evidence of a significant association between the evolutions of DM and cancer, both in terms of overall survival and DM complete clinical response. Immunosuppressive treatments for DM were not significantly associated with mortality.
Study context
- Population
- Patients with cancer-associated DMmedian follow-up 3.92 years
- Participants
- 73 patients
- Outcome
- DM complete clinical response and overall survival
Methodological detailsmulticentre, Cox model with time-dependent covariates, inverse probability censoring weighting
- Multicentre
- Cox model with time-dependent covariates
- Inverse probability censoring weighting
Main finding
As reported in the abstract
Hazard ratio (95% CI)
Cancer remissionDM complete clinical response
2.46(1.13–5.32)
Younger ageDM complete clinical response
0.68(0.49–0.95)
Sustained cancer activitymortality
12.93(2.42–69.25)
Male sexmortality
2.82(1.19–6.70)
Older agemortality
1.86(1.26–2.79)
Sustained DM activitymortality; not associated
0.40(0.13–1.26)
- Cancer remission
- 40 (54.8%)
- DM complete clinical response among those with cancer remission
- 28/40 (70.0%)
Observational data: associations, not effects.
Further findings
Mortality: oral corticosteroid use
| HR (95% CI) | ||
|---|---|---|
| Oral corticosteroid useProtective factor only on univariate analysis · univariate analysis only | 0.18 (0.08–0.42) | |
| 0.050.21520Hazard ratio (log scale) |
Original publication
Prognostic factors for patients with cancer-associated dermatomyositis: a retrospective, multicentre cohort study of 73 patients. Rheumatology (Oxford). Published 26 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →